Tu
Non verificato

Tubulis

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza
21/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Industria
Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications
1.00
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development
1.00
16/12/2025
Eventi
Sanità
Salute
Farmaceutica
Medicina - Varie
Oncologia
Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference
1.00
30/10/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Vetrine/Shopping
Medicina - Varie
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)
1.00
19/10/2025
Scienza
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Eventi
Industria
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
1.00
15/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
1.00
22/09/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025
1.00
09/09/2025
Scienza
Legge/Diritto
Biotecnologia
Farmaceutica
Oncologia
Salute
Associazioni/Professionisti
Mercato del lavoro
Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer
1.00
06/02/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
1.00
30/01/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0